Adrenocortical Carcinoma

Dear Colleagues,

Adrenocortical carcinoma (ACC) is a rare endocrine malignant disease. The management of ACC patients is challenging. Surgery is the mainstay of therapy and represents the only treatment modality that can offer patients a chance of cure. Systemic therapy is still based on mitotane, or the association of mitotane with etoposide, doxorubicin, and cisplatin (EDP-M scheme). The molecular target therapies and immunotherapies tested so far have substantially failed to demonstrate a significant efficacy in ACC.

New therapies are needed, but the rarity of the disease hampers the performance of prospective clinical trials. Since only a few studies can be carried out in this rare pathology, the accurate identification of strong biological rationales deriving from sound preclinical studies is crucial before designing a new trial.

At the same time, we need to optimize the available strategies by the introduction of neoadjuvant and adjuvant therapies before and after surgery in patients with early ACC and the integration of systemic therapies and surgery in advanced ACC.

The prognosis of ACC patients is often dismal but heterogeneous, and the availability of robust prognostic and predictive parameters is of paramount importance.

This Special Issue will focus on the current state of the art and future prospects in the management of ACC at both clinical and preclinical level.

Prof. Alfredo Berruti
Prof. Sandra Sigala
Prof. Guido Alberto Massimo Tiberio
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.